Crossject is revolutionizing needle free injection

Paragraphes
Colonne 1

Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®. The prefilled, single-use device propels the medicine through the skin in less than a tenth of a second. Crossject currently has eight ZENEO® solutions in advanced stages of development, seven of which are for emergency situations.  

Zeneo illustration

 

Our news

Image de l'actualité

Crossject will be attending the 2018 BIO International Convention in Boston

Résumé de l'actualité

Crossject COO Olivier Giré will be attending the 2018 BIO One-on-One Partnering™ in Boston from June 3th to 6th.

Image de l'actualité

ZENEO® Midazolam earns the orphan drug designation

Résumé de l'actualité

The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.